Hall, Jeremy ![]() Item availability restricted. |
![]() |
PDF
- Accepted Post-Print Version
Restricted to Repository staff only until 8 May 2025 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (76kB) |
Official URL: http://dx.doi.org/10.1192/bjp.2024.195
Abstract
Antipsychotic medications targeting dopamine receptors were identified 70 years ago. Recent clinical trials have shown that agonists of muscarinic acetylcholinergic receptors can improve both psychotic and negative symptoms in schizophrenia. Here, this new approach to the treatment of schizophrenia is reviewed in anticipation of the drugs being licensed clinically.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | In Press |
Schools: | Medicine |
Publisher: | Cambridge University Press |
ISSN: | 0007-1250 |
Date of First Compliant Deposit: | 9 January 2025 |
Date of Acceptance: | 7 September 2024 |
Last Modified: | 13 Jan 2025 10:30 |
URI: | https://orca.cardiff.ac.uk/id/eprint/175149 |
Actions (repository staff only)
![]() |
Edit Item |